HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    

Zacks #1 Rank
See how a purely mathematical analysis of earnings estimate revisions returns over 28% per year on average. Click Here to Learn More.
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Top 10 Stocks
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Small Cap Trader
Strategic Investor
Surprise Trader
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


CEPH: Cephalon Inc - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

CEPHALON INC (NASD)
CEPH 65.78 0.78 (1.20%) Vol.  1,669,476 16:00 ET

Day Low - High 64.64 - 66.50
52wk Low - High 52.55 - 79.68
Avg Volume 1,871,291
Industry MED-BIOMED/GENE
Market Cap 4.85 B
Div - Yield 0.00 - 0.00
PE (forward) 10.42
PEG Ratio .78
Current Year Est. 6.24
EPS Last Year 5.82
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Buy12%
# 2Strong Sell50.23%
# 3Hold14%
# 4Sell3.97%
# 5Hold1.85%
S&P50012.22%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


downgraded 02/06/2010
Short-Term Rating 1-3 Months
PREMIUM
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 10/29/2009
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
CEPHALON INC CEPH PREMIUM
GILEAD SCIENCES GILD PREMIUM
GEN-PROBE INC GPRO PREMIUM
AETERNA ZENTARS AEZS PREMIUM
See all MED-BIOMED/GENE Peers

BROKERAGE RECOMMENDATIONS
Current ABR 1.87
ABR (Last Week) 1.87
# of Recs in ABR 23
Average Target Price 71.00
Industry Rank by ABR 67 out of 217
Rank in Industry 97 out of 162
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate CEPH?
Buy
Sell
Find out what the Zacks Community
thinks of CEPH at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 Comparative Chart



 
ZACKS COMMENTARY FOR CEPH
Zacks Blog: Lower Q3 Loss for Alkermes
Feb 05, 2010
Zacks Blog: CEPH Enters Generics Market
Feb 02, 2010
Zacks Blog: Cephalon’s Nuvigil Under Pressure
Jan 07, 2010
Zacks Blog: Valeant Drug Accepted by FDA
Jan 04, 2010
Zacks Blog: FDA Delays Nuvigil Decision
Dec 28, 2009
Zacks Blog: Company News for December 22, 2009
Dec 22, 2009
Zacks Blog: Cephalon Sues Actavis
Dec 11, 2009
Zacks Blog: CEPH Drug Gains on Positive Data
Dec 11, 2009
More Zacks Commentary
NEWS
Cephalon Bullish Moving Average Crossover Alert (CEPH)
Feb 09, 2010
BioClinica Inks Multi-Year Outsourcing Deal with Leading Biopharmaceutical Company
Feb 04, 2010
Cephalon to acquire Mepha
Feb 02, 2010
Cephalon To Buy Mepha
Feb 02, 2010
Closing Update: Stocks End at Day Highs
Feb 01, 2010
Healthcare News: Humana Earnings, Cephalon Deal
Feb 01, 2010
Cephalon, Inc. Announces Agreement to Acquire Mepha AG
Feb 01, 2010
CEPH: Conference call regarding Agreement to Acquire Mepha AG @ 09:00 ET Today [delayed]
Feb 01, 2010
More News
EARNINGS ESTIMATES
  This Quarter
12/2009
Next Quarter
03/2010
This Year
12/2009
Next Year
12/2010
Average Estimate 1.60 1.54 5.96 6.24
Number of Estimates 21 10 22 23
Low Estimates 1.50 1.33 5.86 5.84
High Estimate 2.04 1.66 6.38 6.60
Year Ago EPS 1.46 1.30 4.82 5.96
EPS Growth 9.62% 18.31% 23.66% 4.67%

More Estimates

COMPANY DESCRIPTION
Cephalon is an international biopharmaceutical company focused on the discovery, development and marketing of products to treat sleep disorders, neurological disorders, cancer and pain. In addition to an active research and development program, they market products in the United States and various countries in Europe.

Full Company Report
FINANCIALS
EPS TTM 5.82
Sales 1974.55
Net Income 257.65
Price/Earnings 11.17
Price/Book 2
Price/Cash Flow 8.25
Price/Sales 2.25


More Financials

 
About Zacks | Advertise | Affiliate | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2010 Zacks Investment Research